RO5545965 / Roche - LARVOL DELTA

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics (clinicaltrials.gov) - P1; N=48; Active, not recruiting; Sponsor: Hoffmann-La Roche; Recruiting ➔ Active, not recruiting; Trial primary completion date: Dec 2016 ➔ Apr 2017

Enrollment closed • Trial primary completion date • Biosimilar • CNS Disorders • Schizophrenia